The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - IAVI Neutralizing Antibody Center; Harvard University - Ragon Institute of MGH, MIT and Harvard
The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - IAVI Neutralizing Antibody Center
International AIDS Vaccine Initiative; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
International AIDS Vaccine Initiative; The Scripps Research Institute - Department of Immunology and Microbiology; The Scripps Research Institute - Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery; The Scripps Research Institute - IAVI Neutralizing Antibody Center
The VH1-2 restricted VRC01-class of antibodies targeting the HIV Envelope CD4 binding site (CD4bs) are a major focus of HIV vaccine strategies. While enormous progress has been made in the activation of VRC01-class antibody precursors by immunization, challenges remain in understanding how to drive such responses towards the neutralization breadth characteristic of this family of antibodies. To inform these strategies, we describe here the rapid development of a VRC01-class antibody lineage in the subtype C infected IAVI Protocol C neutralizer PC063. PCIN63 monoclonal antibodies have the hallmark VRC01-class features and demonstrate neutralization breadth similar to the prototype VRC01 antibody but are 3 to 4-fold less mutated. Maturation occurred rapidly within ~24 months of emergence of the lineage and somatic hypermutations accumulated at key contact residues. This first longitudinal study of broadly neutralizing VRC01-class antibody lineage reveals early binding to the N276-glycan during affinity maturation, which may have implications for vaccine design.
Umotoy, Jeffrey and Bagaya, Bernard and Joyce, Collin and Menis, Sergey and Schiffner, Torben and Mohan, Sanjay and Vollbrecht, Thomas and Kalyuzhniy, Oleksander and Madzorera, Sharon and Kitchin, Dale and Lambson, Bronwen and Nonyane, Molati and Kilembe, William and Investigators, The IAVI Protocol C and Network, The IAVI African HIV Research and Poignard, Pascal and Schief, William R. and Burton, Dennis R. and Murrell, Ben and Moore, Penny L. and Briney, Bryan and Sok, Devin and Landais, Elise, Rapid and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan (December 4, 2018). Available at SSRN: https://ssrn.com/abstract=3295647 or http://dx.doi.org/10.2139/ssrn.3295647
This is a paper under consideration at Cell Press and has not been peer-reviewed.
Subscribe to this free journal for more curated articles on this topic
FOLLOWERS
8
PAPERS
3,497
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.